source
- Pharma pours billions into bispecifics, ADCs and cell therapies despite limited clinical proofThe article notes that emerging drug formats such as bispecific antibodies, antibody‑drug conjugates and cell therapies have yet to demonstrate clear clinical success, yet pharmaceutical firms cont…
- EY report says MedTech growth driven by commercial leaders, AI and expanding into new care settingsThe latest EY Pulse of the MedTech Industry report looks at the period from 2025 through the first half of 2026. It finds that innovation has spurred more dealmaking and R&D spending, while artific…